ClinicalTrials.gg
CompletedNCT01634243Updated Mar 19, 2014Results posted

A Dose-ranging Study for SPM 962 in Parkinson's Disease Patients

A Phase 2 interventional study of SPM 962 in Parkinson's Disease, sponsored by Otsuka Pharmaceutical Co., Ltd.. Completed at 5 sites in Japan. Open to participants aged 30 Years to 79 Years. Per ClinicalTrials.gov, last updated 2014-03-19.

Sponsored by Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
64
Allocation
Not applicable
Ages
30 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 44 studies testing rotigotine in Parkinson Disease — 1 open to participants now, 1 under way, none of them phase 3. rotigotine · Parkinson Disease.

Enrollment
29th of 42
64 · median 123
Started
2005
with 1 other
Phase 2
7 of 44
none open now
Registered
28th of 44
by date
Lead sponsor
7 of 44
Otsuka Pharmaceutical Co., Ltd.

Among the 44 studies testing rotigotine in Parkinson Disease, this one is the 29th largest by enrollment of the 42 interventional ones that give a count, is one of 2 that started in 2005, is one of 7 in phase 2, and was the 28th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

1 of the 44 studies testing rotigotine in Parkinson Disease is open now. Recruiting first, the newest first:

About rotigotine

rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.

This study: 30 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing rotigotine in Parkinson Disease, or all of them as a file.
02

Study summary

The primary objective of this trial is to establish the maximum maintenance dose of SPM 962 in patients with Parkinson's disease in a multi-center, uncontrolled, open-label study by conducting safety evaluation of each patient following once-daily transdermal doses of SPM 962 within a range of 4.5 to 36.0 mg. (The administration period will consist of a standard 8-week dose-titration period, 4-week dose-maintenance period, and a dose de-escalation period) Exploratory evaluation of each patient's maintenance dose will also be conducted with attention to patient safety. The relationship of pharmacokinetics, safety, and efficacy will also be examined.

03

Conditions studied

  • Parkinson's Disease

Browse trials for

Keywords

  • SPM 962
  • rotigotine
  • Parkinson's disease
04

Who can participate

Ages eligible
30 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For subject with early and advanced Parkinson's disease

    • Subject diagnosed as having Parkinson's disease in accordance with "Diagnostic Criteria established by the Research Committee of MHLW-specified Intractable Neurodegenerative Diseases (1995)".
    • Subject is 30 and more and less than 80 years of age at the time of .
    • Gender and inpatient-outpatient status are not specified.
  • For subject with early Parkinson's disease

    • Hoehn \& Yahr stage 3 or less.
    • Subject who has not taken L-dopa within 28 days prior to initial administration of SPM 962.
  • For subject with dvanced Parkinson's disease

    • Hoehn \& Yahr stage 2-4.
    • Subject is on a stable dose of L-dopa with no change in daily dose or dosing regimen for at least 7 days prior to the initial treatment of SPM 962.
    • Subject has any of the following problematic symptoms; 1) Wearing off phenomenon 2) On and off phenomenon 3) Not well controlled with L-dopa due to adverse effect 4) Weakening of L-dopa efficacy.

Exclusion criteria

Exclusion Criteria:

  • Subject is on other dopamine agonist treatment within 7 days prior to the initial treatment. Subject is on cabergoline treatment within 14 days prior to the initial treatment.
  • Subject has psychiatric symptoms, e.g. confusion, hallucination, delusion, excitation, delirium, abnormal behavior.
  • Subject has orthostatic hypotension.
  • Subject has a history of epilepsy, convulsion and other.
  • Subject has a complication of serious cardiac disorder or has the history.
  • Subject has arrhythmia and treated with class 1a antiarrhythmic drugs (e.g. quinidine, procainamide etc.) or class 3 antiarrhythmic drugs (e.g. amiodarone, sotalol etc.).
  • At screening and baseline, subject develops serious abnormality. Subjects has -interval >450 msec at screening. Subject has QTc-interval >450 msec in males and >470 msec in females at baseline.
  • Subject has congenital long QT syndrome.
  • Subject has hypokalaemia.
  • Subject has a total >= 3.0 mg/dL or (GOT) or ALT(GPT) greater than 2.5 times of the upper limit of the reference range (or >= 100 IU/L).
  • Subject has BUN >= 25 mg/dL or serum creatinine >= 2.0 mg/dl.
  • Subject has a history of allergic reaction to topical agents such as transdermal patch.
  • Subject is pregnant or nursing or woman who plans pregnancy during the trial.
  • Subject is receiving therapy with prohibited drug specified in the study protocol.
  • Subject has a history of pallidotomy, thalamotomy, deep brain stimulation or fetal tissue transplant.
  • Subject has dementia.
  • Subject is unable to give consent.
  • Subject is participating in another trial of an drug or done so within 6 months prior to the initial treatment.
  • Investigator judges that subject is inappropriate as a study subject with other reasons.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    SPM 962

    SPM 962 transdermal patch

    Drug: SPM 962

Interventions

  • SPM 962 transdermal patch once a daily up to 36.0 mg/day

    Also known as: rotigotine

06

What researchers measure

Primary outcomes

  1. Maintenance Dose of the SPM962

    The maintenance dose of the SPM 962 was examined based on the safety and efficacy.

    Time frame: Up to 12 weeks after dosing

Secondary outcomes

  1. Incidence and Severity of Adverse Events, Vital Signs, and Laboratory Parameters

    Incidence and severity of adverse events, vital signs, and laboratory parameters following the initiation of study treatment.

    Time frame: Up to 12 weeks after dosing

  2. Total of Unified Parkinson's Disease Rating Scale (UPDRS) Part 2 Sum Score and Part 3 Sum Score for Early Parkinson's Disease Without Concomitant L-dopa Therapy

    Mean change (LOCF) from baseline in Total of UPDRS Part 2 sum score and Part 3 sum at 12 weeks after dosing. UPDRS is a scale for monitoring Parkinson's Disease-related disability and impairment. The UPDRS consists of the following four sub-scales. Part 1: Mentation, Part 2: Activities of Daily Living, Part 3: Motor, Part 4: Complications. Part 2 assesses 13 items and Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

    Time frame: baseline, 12 weeks after dosing

  3. UPDRS Part 3 Sum Score for Advanced Parkinson's Disease With Concomitant L-dopa Therapy

    Mean change (LOCF) from baseline in UPDRS Part 3 sum score at 12 weeks after dosing. UPDRS sub-scale Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

    Time frame: baseline, 12 weeks after dosing

  4. UPDRS Part 2 Sum Score for Early Parkinson's Disease Without Concomitant L-dopa Therapy

    Mean change (LOCF) from baseline in UPDRS Part 2 sum score at 12 weeks after dosing. UPDRS sub-scale Part 2 assesses 13 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

    Time frame: Baseline, 12 weeks after dosing

  5. UPDRS Part 3 Sum Score for Early Parkinson's Disease Without Concomitant L-dopa Therapy

    Mean change (LOCF) from baseline in UPDRS Part 3 sum score at 12 weeks after dosing. UPDRS sub-scale Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

    Time frame: Baseline, 12 weeks after dosing

  6. UPDRS Part 2 Sum Score (on State) for Advanced Parkinson's Disease With Concomitant L-dopa Therapy.

    Mean change (LOCF) from baseline in UPDRS Part 2 sum score (on state) at 12 weeks after dosing. UPDRS sub-scale Part 2 assesses 13 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

    Time frame: Baseline, 12 weeks after dosing

  7. UPDRS Part 2 Sum Score (Off State) for Advanced Parkinson's Disease With Concomitant L-dopa Therapy.

    Mean change (LOCF) from baseline in UPDRS Part 2 sum score (off state) at 12 weeks after dosing. UPDRS sub-scale Part 2 assesses 13 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

    Time frame: Baseline, 12 weeks after dosing

  8. UPDRS Part 2 Sum Score (Average Score of on State and Off State) for Advanced Parkinson's Disease With Concomitant L-dopa Therapy

    Mean change (LOCF) from baseline in UPDRS Part 2 sum score (average score of on state and off state) at 12 weeks after dosing. UPDRS sub-scale Part 2 assesses 13 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

    Time frame: Baseline, 12 weeks after dosing

  9. Total of UPDRS Part 2 Sum Score (Average Score of on State and Off State) and Part 3 Sum Score for Advanced Parkinson's Disease With Concomitant L-dopa Therapy

    Mean change (LOCF) from baseline in Total of UPDRS Part 2 sum score (average score of on state and off state) and Part 3 sum score at 12 weeks after dosing. UPDRS sub-scale Part 2 assesses 13 items and Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

    Time frame: Baseline, 12 weeks after dosing

  10. Off Time for Advanced Parkinson's Disease With Concomitant L-dopa Therapy

    Mean change (LOCF) from baseline in off time at 12 weeks after dosing.

    Time frame: Baseline, 12 weeks after dosing

07

Results

Posted Mar 19, 2014

Participant flow

Participant flow — Overall Study
MilestoneEarly-stage Parkinson's DiseaseAdvanced Parkinson's Disease
Started2143
Completed1538
Not completed65
Withdrew: Adverse event55
Withdrew: Lack of efficacy10

Outcome measures

PrimaryMaintenance Dose of the SPM962

The maintenance dose of the SPM 962 was examined based on the safety and efficacy.

Time frame:
Up to 12 weeks after dosing
Reported as:
Number · participants
Maintenance Dose of the SPM962
participantsEarly-stage Parkinson's DiseaseAdvanced Parkinson's Disease
4.5 mg00
9.0 mg01
13.5 mg05
18.0 mg35
22.5 mg29
27.0 mg29
31.5 mg23
36.0 mg88
SecondaryIncidence and Severity of Adverse Events, Vital Signs, and Laboratory Parameters

Incidence and severity of adverse events, vital signs, and laboratory parameters following the initiation of study treatment.

Time frame:
Up to 12 weeks after dosing
Reported as:
Number · participants
Incidence and Severity of Adverse Events, Vital Signs, and Laboratory Parameters
participantsEarly-stage Parkinson's DiseaseAdvanced Parkinson's Disease
Any AEs2041
Treatment-related AEs1936
SAEs13
Severe AEs11
Discontinuation due to AEs55
Death00
AEs related to laboratory parameters78
Discontinuation due to AEs related to labs01
Clinically significant QTc prolongation00
SecondaryTotal of Unified Parkinson's Disease Rating Scale (UPDRS) Part 2 Sum Score and Part 3 Sum Score for Early Parkinson's Disease Without Concomitant L-dopa Therapy

Mean change (LOCF) from baseline in Total of UPDRS Part 2 sum score and Part 3 sum at 12 weeks after dosing. UPDRS is a scale for monitoring Parkinson's Disease-related disability and impairment. The UPDRS consists of the following four sub-scales. Part 1: Mentation, Part 2: Activities of Daily Living, Part 3: Motor, Part 4: Complications. Part 2 assesses 13 items and Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

Time frame:
baseline, 12 weeks after dosing
Reported as:
Mean · Scores on a scale
Total of Unified Parkinson's Disease Rating Scale (UPDRS) Part 2 Sum Score and Part 3 Sum Score for Early Parkinson's Disease Without Concomitant L-dopa Therapy
Scores on a scaleEarly-stage Parkinson's DiseaseAdvanced Parkinson's Disease
Total of Unified Parkinson's Disease Rating Scale (UPDRS) Part 2 Sum Score and Part 3 Sum Score for Early Parkinson's Disease Without Concomitant L-dopa Therapy-8.4 ± 11.2—
SecondaryUPDRS Part 3 Sum Score for Advanced Parkinson's Disease With Concomitant L-dopa Therapy

Mean change (LOCF) from baseline in UPDRS Part 3 sum score at 12 weeks after dosing. UPDRS sub-scale Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

Time frame:
baseline, 12 weeks after dosing
Reported as:
Mean · Scores on a scale
UPDRS Part 3 Sum Score for Advanced Parkinson's Disease With Concomitant L-dopa Therapy
Scores on a scaleEarly-stage Parkinson's DiseaseAdvanced Parkinson's Disease
UPDRS Part 3 Sum Score for Advanced Parkinson's Disease With Concomitant L-dopa Therapy—-11.7 ± 10.1
SecondaryUPDRS Part 2 Sum Score for Early Parkinson's Disease Without Concomitant L-dopa Therapy

Mean change (LOCF) from baseline in UPDRS Part 2 sum score at 12 weeks after dosing. UPDRS sub-scale Part 2 assesses 13 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

Time frame:
Baseline, 12 weeks after dosing
Reported as:
Mean · Scores on a scale
UPDRS Part 2 Sum Score for Early Parkinson's Disease Without Concomitant L-dopa Therapy
Scores on a scaleEarly-stage Parkinson's DiseaseAdvanced Parkinson's Disease
UPDRS Part 2 Sum Score for Early Parkinson's Disease Without Concomitant L-dopa Therapy-1.5 ± 2.4—
SecondaryUPDRS Part 3 Sum Score for Early Parkinson's Disease Without Concomitant L-dopa Therapy

Mean change (LOCF) from baseline in UPDRS Part 3 sum score at 12 weeks after dosing. UPDRS sub-scale Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

Time frame:
Baseline, 12 weeks after dosing
Reported as:
Mean · Scores on a scale
UPDRS Part 3 Sum Score for Early Parkinson's Disease Without Concomitant L-dopa Therapy
Scores on a scaleEarly-stage Parkinson's DiseaseAdvanced Parkinson's Disease
UPDRS Part 3 Sum Score for Early Parkinson's Disease Without Concomitant L-dopa Therapy-6.9 ± 9.0—
SecondaryUPDRS Part 2 Sum Score (on State) for Advanced Parkinson's Disease With Concomitant L-dopa Therapy.

Mean change (LOCF) from baseline in UPDRS Part 2 sum score (on state) at 12 weeks after dosing. UPDRS sub-scale Part 2 assesses 13 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

Time frame:
Baseline, 12 weeks after dosing
Reported as:
Mean · Scores on a scale
UPDRS Part 2 Sum Score (on State) for Advanced Parkinson's Disease With Concomitant L-dopa Therapy.
Scores on a scaleEarly-stage Parkinson's DiseaseAdvanced Parkinson's Disease
UPDRS Part 2 Sum Score (on State) for Advanced Parkinson's Disease With Concomitant L-dopa Therapy.—-2.6 ± 3.2
SecondaryUPDRS Part 2 Sum Score (Off State) for Advanced Parkinson's Disease With Concomitant L-dopa Therapy.

Mean change (LOCF) from baseline in UPDRS Part 2 sum score (off state) at 12 weeks after dosing. UPDRS sub-scale Part 2 assesses 13 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

Time frame:
Baseline, 12 weeks after dosing
Reported as:
Mean · Scores on a scale
UPDRS Part 2 Sum Score (Off State) for Advanced Parkinson's Disease With Concomitant L-dopa Therapy.
Scores on a scaleEarly-stage Parkinson's DiseaseAdvanced Parkinson's Disease
UPDRS Part 2 Sum Score (Off State) for Advanced Parkinson's Disease With Concomitant L-dopa Therapy.—-4.0 ± 5.2
SecondaryUPDRS Part 2 Sum Score (Average Score of on State and Off State) for Advanced Parkinson's Disease With Concomitant L-dopa Therapy

Mean change (LOCF) from baseline in UPDRS Part 2 sum score (average score of on state and off state) at 12 weeks after dosing. UPDRS sub-scale Part 2 assesses 13 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

Time frame:
Baseline, 12 weeks after dosing
Reported as:
Mean · Scores on a scale
UPDRS Part 2 Sum Score (Average Score of on State and Off State) for Advanced Parkinson's Disease With Concomitant L-dopa Therapy
Scores on a scaleEarly-stage Parkinson's DiseaseAdvanced Parkinson's Disease
UPDRS Part 2 Sum Score (Average Score of on State and Off State) for Advanced Parkinson's Disease With Concomitant L-dopa Therapy—-3.2 ± 3.7
SecondaryTotal of UPDRS Part 2 Sum Score (Average Score of on State and Off State) and Part 3 Sum Score for Advanced Parkinson's Disease With Concomitant L-dopa Therapy

Mean change (LOCF) from baseline in Total of UPDRS Part 2 sum score (average score of on state and off state) and Part 3 sum score at 12 weeks after dosing. UPDRS sub-scale Part 2 assesses 13 items and Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.

Time frame:
Baseline, 12 weeks after dosing
Reported as:
Mean · Scores on a scale
Total of UPDRS Part 2 Sum Score (Average Score of on State and Off State) and Part 3 Sum Score for Advanced Parkinson's Disease With Concomitant L-dopa Therapy
Scores on a scaleEarly-stage Parkinson's DiseaseAdvanced Parkinson's Disease
Total of UPDRS Part 2 Sum Score (Average Score of on State and Off State) and Part 3 Sum Score for Advanced Parkinson's Disease With Concomitant L-dopa Therapy—-14.0 ± 11.6
SecondaryOff Time for Advanced Parkinson's Disease With Concomitant L-dopa Therapy

Mean change (LOCF) from baseline in off time at 12 weeks after dosing.

Time frame:
Baseline, 12 weeks after dosing
Reported as:
Mean · Hours
Off Time for Advanced Parkinson's Disease With Concomitant L-dopa Therapy
HoursEarly-stage Parkinson's DiseaseAdvanced Parkinson's Disease
Off Time for Advanced Parkinson's Disease With Concomitant L-dopa Therapy—-1.98 ± 1.3

Adverse events

Collected over 5 to 13 weeks depending on maintenance dose. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Early-stage Parkinson's Disease—1/21 (4.8%)20/21 (95.2%)
Advanced Parkinson's Disease—3/43 (7%)41/43 (95.3%)
Most frequent serious events
Most frequent serious events
EventEarly-stage Parkinson's DiseaseAdvanced Parkinson's Disease
Carcinoma ProstateNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/210/43
PneumoniaInfections and infestations0/211/43
Abnormal BehaviourPsychiatric disorders0/211/43
Suicide AttemptPsychiatric disorders0/211/43
Most frequent other events
Showing 10 of 22
Most frequent other events
EventEarly-stage Parkinson's DiseaseAdvanced Parkinson's Disease
Administration Site ReactionGeneral disorders16/2120/43
NauseaGastrointestinal disorders8/219/43
NasopharyngitisInfections and infestations6/214/43
VomitingGastrointestinal disorders4/215/43
SomnolenceNervous system disorders4/217/43
InsomniaPsychiatric disorders4/214/43
ConstipationGastrointestinal disorders3/214/43
Blood Urea IncreasedInvestigations3/211/43
DizzinessNervous system disorders3/213/43
AnorexiaMetabolism and nutrition disorders2/215/43

Baseline characteristics

Age, Continuous
Age, Continuous(years)Early-stage Parkinson's DiseaseAdvanced Parkinson's DiseaseTotal
Mean64.3 ± 6.964.7 ± 7.664.6 ± 7.3
Age, Categorical
Age, Categorical(Participants)Early-stage Parkinson's DiseaseAdvanced Parkinson's DiseaseTotal
<=18 years000
Between 18 and 65 years122032
>=65 years92332
Sex: Female, Male
Sex: Female, Male(Participants)Early-stage Parkinson's DiseaseAdvanced Parkinson's DiseaseTotal
Female122941
Male91423
Region of Enrollment
Region of Enrollment(participants)Early-stage Parkinson's DiseaseAdvanced Parkinson's DiseaseTotal
Japan214364
08

Study locations

5 sites
  • Kanto Region, Japan
  • Kinki Region, Japan
  • Kyushu Region, Japan
  • Shikoku Region, Japan
  • Tohoku Region, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2005, a primary completion of May 2006 and a completion of May 2006. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2014, 7 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2012
First posted
Jul 6, 2012
Start
Jan 2005
Primary completionActual
May 2006
CompletionActual
May 2006
Results first posted
Mar 19, 2014
Last update
Mar 19, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01634243
Responsible party
Sponsor
First posted
Jul 6, 2012
Start date
Jan 2005
Primary completion
May 2006
Completion
May 2006
Results posted
Mar 19, 2014
Last update
Mar 19, 2014

Study contacts

Kyoji Imaoka, Mr
study director · Otsuka Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rotigotine

Start the discussion